Jerry Fahrni

The FDA has issued an update to the previous alert on the interaction between calcium and ceftriaxone (Rocephin). The original warning was based on reported fatalities involving neonates. The update occurred after Roche (manufacturer of ceftriaxone) conducted two studies using neonatal and adult plasma with varying concentrations of ceftriaxone and calcium. Based on the results, ceftriaxone and calcium-containing products may now be used concomitantly in patients greater than 28 days old.